Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Berzosertib, which is licensed by Merck KGaA, Darmstadt, Germany, is being investigated in separate early- and mid-stage clinical trials in combination with chemotherapy as a possible treatment for small-cell lung cancer, ovarian cancer and other types of tumors.
Lead Product(s): Berzosertib
Therapeutic Area: Infections and Infectious Diseases Product Name: M6620
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: UCLA Jonsson Comprehensive Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2021
Details:
Treatment with Adrecizumab showed an encouraging outcome in this limited data set, seven out of eight patients survived the observation period. Adrecizumab targets Adrenomedullin to restore endothelial barrier function and impaired vascular integrity.
Lead Product(s): Adrecizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: HAM8101
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Under the contract, Vibalogics will produce multiple batches of the vaccine candidate at its facility in Cuxhaven, Germany, expected to yield thousands of vaccine doses.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 19, 2020
Details:
Through this partnership, an integrated plant design combines Exyte’s prefabricated modular construction system, ExyCell, with Univercells Technologies’ NevoLine biomanufacturing platform featuring the scale-X fixed-bed bioreactor at its core.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Univercells
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 14, 2020
Details:
The strategic collaboration focuses on discovery and development of anti-viral drug candidates for COVID-19.
Lead Product(s): Antiviral drugs
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Anixa Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 20, 2020
Details:
Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug’s use in the U.S.
Lead Product(s): Chloroquine Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 19, 2020
